Literature DB >> 25187273

Combining radiation and immunotherapy: a new systemic therapy for solid tumors?

Chad Tang1, Xiaohong Wang1, Hendrick Soh2, Steven Seyedin1, Maria Angelica Cortez1, Sunil Krishnan1, Erminia Massarelli3, David Hong4, Aung Naing4, Adi Diab5, Daniel Gomez1, Huiping Ye1, John Heymach3, Ristuko Komaki1, James P Allison6, Padmanee Sharma7, James W Welsh8.   

Abstract

With the recent success of checkpoint inhibitors and other immunomodulating agents, there has been renewed interest in the combination of such agents with radiation. The biologic premise behind such a strategy is that the tumor-antigen release achieved by localized radiation will promote specific tumor targeting by the adaptive immune system, which can be augmented further by systemic immune-stimulating agents. In this manner, clinicians hope to induce a phenomenon known as the abscopal effect, whereby localized radiation results in immune-mediated tumor regression in disease sites well outside of the radiation field. Herein, we present a comprehensive overview of the early clinical and preclinical evidence behind this approach. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25187273      PMCID: PMC5367158          DOI: 10.1158/2326-6066.CIR-14-0069

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  69 in total

1.  Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

Authors:  Masayoshi Ishida; Yoshiko Iwai; Yoshimasa Tanaka; Taku Okazaki; Gordon J Freeman; Nagahiro Minato; Tasuku Honjo
Journal:  Immunol Lett       Date:  2002-10-21       Impact factor: 3.685

2.  Molecular basis of T cell inactivation by CTLA-4.

Authors:  K M Lee; E Chuang; M Griffin; R Khattri; D K Hong; W Zhang; D Straus; L E Samelson; C B Thompson; J A Bluestone
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

3.  Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.

Authors:  L Serrone; M Zeuli; F M Sega; F Cognetti
Journal:  J Exp Clin Cancer Res       Date:  2000-03

Review 4.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

5.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

6.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Authors:  S F Slovin; C S Higano; O Hamid; S Tejwani; A Harzstark; J J Alumkal; H I Scher; K Chin; P Gagnier; M B McHenry; T M Beer
Journal:  Ann Oncol       Date:  2013-03-27       Impact factor: 32.976

7.  Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction.

Authors:  C M Roberts; E Foulcher; J J Zaunders; D H Bryant; J Freund; D Cairns; R Penny; G W Morgan; S N Breit
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

Authors:  Maria Grazia Ruocco; Karsten A Pilones; Noriko Kawashima; Michael Cammer; Julie Huang; James S Babb; Mengling Liu; Silvia C Formenti; Michael L Dustin; Sandra Demaria
Journal:  J Clin Invest       Date:  2012-09-04       Impact factor: 14.808

10.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Authors:  Inge Verbrugge; Jim Hagekyriakou; Leslie L Sharp; Mara Galli; Alison West; Nicole M McLaughlin; Hélène Duret; Hideo Yagita; Ricky W Johnstone; Mark J Smyth; Nicole M Haynes
Journal:  Cancer Res       Date:  2012-05-08       Impact factor: 12.701

View more
  111 in total

Review 1.  Strategies for combining immunotherapy with radiation for anticancer therapy.

Authors:  Steven N Seyedin; Jonathan E Schoenhals; Dean A Lee; Maria A Cortez; Xiaohong Wang; Sharareh Niknam; Chad Tang; David S Hong; Aung Naing; Padmanee Sharma; James P Allison; Joe Y Chang; Daniel R Gomez; John V Heymach; Ritsuko U Komaki; Laurence J Cooper; James W Welsh
Journal:  Immunotherapy       Date:  2015-08-27       Impact factor: 4.196

2.  Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab.

Authors:  Tijana Skrepnik; Srinath Sundararajan; Haiyan Cui; Baldassarre Stea
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

Review 3.  Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.

Authors:  Mathieu Rouanne; Mathieu Roumiguié; Nadine Houédé; Alexandra Masson-Lecomte; Pierre Colin; Géraldine Pignot; Stéphane Larré; Evanguelos Xylinas; Morgan Rouprêt; Yann Neuzillet
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

4.  Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.

Authors:  Emily Z Keung; Jen-Wei Tsai; Ali M Ali; Janice N Cormier; Andrew J Bishop; B Ashleigh Guadagnolo; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Jennifer A Wargo; Alexander J Lazar; Wei-Lien Wang; Christina L Roland
Journal:  Oncoimmunology       Date:  2017-10-31       Impact factor: 8.110

5.  "In situ" vaccination for systemic effects in follicular lymphoma.

Authors:  Arne Kolstad; Johanna Olweus
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

6.  Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.

Authors:  Miho Kono; Pamela K Allen; Steven H Lin; Xiong Wei; Melenda D Jeter; James W Welsh; James D Cox; Ritsuko Komaki
Journal:  J Thorac Oncol       Date:  2017-08-10       Impact factor: 15.609

7.  PD-L1 expression in lung cancer.

Authors:  Chad Tang; Joe Y Chang
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

8.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

Review 9.  Antitumor Antibodies Can Drive Therapeutic T Cell Responses.

Authors:  K Dane Wittrup
Journal:  Trends Cancer       Date:  2017-07-29

10.  Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment.

Authors:  Ayman J Oweida; Shilpa Bhatia; Benjamin Van Court; Laurel Darragh; Natalie Serkova; Sana D Karam
Journal:  J Vis Exp       Date:  2019-04-22       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.